Parkinson’s disease, a progressive neurodegenerative condition affecting millions globally, is characterized by a complex constellation of symptoms including involuntary tremors, rigidity, slowed movement, and cognitive impairments, profoundly diminishing the quality of life for those afflicted. While existing therapeutic interventions, ranging from pharmaceutical management to advanced surgical procedures like deep brain stimulation, offer symptomatic relief, they fall short of halting the disease’s relentless march or providing a definitive cure, leaving a significant unmet need for more effective strategies.
A groundbreaking international collaboration, spearheaded by China’s Changping Laboratory and involving researchers from Washington University School of Medicine in St. Louis and other esteemed institutions, has pinpointed a specific neural network intricately linked to the core manifestations of Parkinson’s disease. This pivotal discovery identifies the somato-cognitive action network, or SCAN, as a critical player in the pathogenesis of the disorder. Crucially, when this network was precisely targeted using transcranial magnetic stimulation (TMS), a non-invasive neuromodulatory technique, patients exhibited a more than twofold improvement in their symptoms compared to instances where stimulation was applied to adjacent brain regions.
These findings, meticulously detailed in the February 4th edition of the prestigious journal Nature, signal a paradigm shift in our comprehension of Parkinson’s disease, heralding a new era of highly individualized and geographically precise therapeutic interventions. Dr. Nico U. Dosenbach, a co-author of the study and the David M. & Tracy S. Holtzman Professor of Neurology at WashU Medicine, emphasized the profound implications of this research, stating, "This work unequivocally demonstrates that Parkinson’s is, at its heart, a SCAN disorder, and our data strongly indicate that by targeting the SCAN with personalized, accurate interventions, we can achieve significantly better outcomes than previously thought possible." He further posited that modulating activity within the SCAN holds the potential not merely to alleviate symptoms but to fundamentally alter the disease’s trajectory, potentially slowing or even reversing its progression.
The SCAN, first elucidated by Dr. Dosenbach in a 2023 publication in Nature, is strategically situated within the motor cortex, the brain’s command center for voluntary movement. Its primary function involves the intricate translation of intended actions into executable physical commands and the subsequent monitoring of their execution. Given that Parkinson’s disease extends its influence far beyond motor control, impacting vital functions such as digestion, sleep regulation, motivation, and cognitive processes, senior author Dr. Hesheng Liu, in conjunction with Dr. Dosenbach, embarked on an investigation to ascertain whether dysfunctions within the SCAN could account for this wide-ranging symptomatic spectrum and simultaneously offer a viable therapeutic target.
To rigorously test this hypothesis, Dr. Liu’s team undertook an extensive analysis of brain imaging data drawn from a diverse cohort exceeding 800 participants, gathered from multiple research centers across both the United States and China. This comprehensive dataset included individuals diagnosed with Parkinson’s disease who were undergoing various therapeutic regimens, including deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), focused ultrasound, and pharmacological treatments. For comparative purposes, the study also incorporated data from healthy volunteers and individuals presenting with other movement disorders.
The comprehensive analysis revealed a significant pattern: Parkinson’s disease is characterized by aberrant and excessive connectivity between the SCAN and the subcortical regions of the brain, areas known to play crucial roles in emotion, memory, and motor regulation. Intriguingly, across all four therapeutic modalities investigated, the efficacy of the treatments was directly correlated with their ability to mitigate this hyperconnectivity. The restoration of a more balanced functional relationship between the SCAN and these subcortical structures appeared to normalize activity within the neural circuits responsible for the planning and coordination of motor actions.
"For many decades, Parkinson’s disease has been predominantly conceptualized as a disorder primarily affecting motor deficits and the basal ganglia, the brain’s core motor control center," Dr. Liu remarked, underscoring the transformative nature of their findings. "Our research conclusively demonstrates that the disease originates from a much more pervasive network dysfunction. The SCAN exhibits heightened connectivity with key brain regions implicated in Parkinson’s disease, and this maladaptive wiring disrupts not only motor execution but also a cascade of related cognitive and autonomic functions."
Building upon these foundational insights, the research team engineered a sophisticated precision treatment system meticulously designed to target the SCAN with unparalleled accuracy, employing non-invasive methods. This innovative approach leverages transcranial magnetic stimulation, delivering focused magnetic pulses to specific brain areas via a device positioned externally on the scalp. In a subsequent clinical trial involving 18 patients who received SCAN-targeted stimulation, an impressive 56% demonstrated a positive therapeutic response after just two weeks of treatment. In stark contrast, only 22% of 18 patients who received stimulation directed at nearby, non-SCAN regions experienced improvement, highlighting a remarkable 2.5-fold increase in therapeutic effectiveness for the SCAN-targeted approach.
Dr. Dosenbach highlighted the significant advantage of non-invasive neuromodulatory techniques, noting, "With non-invasive treatments, we have the potential to initiate neuromodulation much earlier in the disease progression than is currently feasible with DBS, as these methods bypass the need for brain surgery."
He further stressed that while these findings represent a monumental leap forward, additional foundational research remains imperative to fully elucidate the intricate contributions of distinct SCAN sub-regions to the diverse spectrum of Parkinson’s symptoms.
Looking toward the future, Dr. Dosenbach is spearheading plans for new clinical trials through Turing Medical, a startup he co-founded at WashU Medicine. These trials will rigorously evaluate a novel non-invasive therapy utilizing surface electrode arrays placed over SCAN regions, specifically aimed at addressing gait disturbances in individuals with Parkinson’s disease. Additionally, he intends to explore the potential of low-intensity focused ultrasound as another non-invasive modality for modulating SCAN activity through acoustic energy.
This transformative research was generously supported by grants from the Changping Laboratory, the U.S. National Institutes of Health (including grant numbers MH096773, MH122066, MH121276, MH124567, NS129521, NS088590, R01NS131405, U01NS098969, and U01NS117836), the National Natural Science Foundation of China (grant numbers 81527901, 81720108021, 81971689, 31970979, and 82090034), the National Key R&D Program of China (2017YFE0103600), the Intellectual and Developmental Disabilities Research Center, the Kiwanis Foundation, the Washington University Hope Center for Neurological Disorders, and the Collaborative Innovation Center of Neuropsychiatric Disorders and Mental Health of Anhui Province (2020xkjT05). The views expressed in this publication are solely those of the authors and do not necessarily reflect the official policies or positions of the National Institutes of Health.
Potential conflicts of interest have been disclosed. H.L. serves as the chief scientist of Neural Galaxy Inc. L.L. is a member of the scientific advisory board for Beijing Pins Medical Co., Ltd. and holds patents related to deep brain stimulation devices. N.U.F.D. has a financial interest in Turing Medical Inc. and may benefit from the commercial success of their neuromodulation targeting software and systems. E.M.G. and N.U.F.D. may receive royalties from FIRMM motion monitoring technology developed at Washington University School of Medicine and licensed to Turing Medical Inc. N.U.F.D. is a co-founder of Turing Medical Inc. These potential conflicts have been reviewed and are managed by Washington University School of Medicine. S.L. provides consulting services to Iota Biosciences. P.A.S. receives fellowship education support from Medtronic and Boston Scientific.
About the Author
